-Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will stop its cell therapy initiatives and look for a partner to advance its research and clinic-ready programs in this field.

The company said it currently has no active clinical trials utilizing cell therapy technology. It will now focus on other types of treatments, including small molecule drugs, biologics and antibody-drug conjugates.

Takeda has spent years working on cell therapies, including experimental treatments that use modified immune cells to target cancer. The company, however, is now redirecting its investments toward areas where it can deliver innovative medicines to patients faster and at greater scale.

The drugmaker said it expects to recognize an impairment loss of about 58.0 billion Japanese yen ($395.47

See Full Page